Medicinal composition for treating vaginitis

A composition and technology of fungal vaginitis, applied in the field of medicine, can solve the problems of not advocating long-term application of drugs and no observed systemic hormone effects, etc., achieve obvious antipruritic and pain-relieving effects, shorten the course of treatment, and have less toxic and side effects

Inactive Publication Date: 2010-10-13
杨军
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] 2) Only 1% of promestrine enters the whole body after being applied on the skin, and no systemic hormone effect is observed after vaginal administration, especially e...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating vaginitis
  • Medicinal composition for treating vaginitis
  • Medicinal composition for treating vaginitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1: prepare the soft capsule of pharmaceutical composition of the present invention

[0028] Proestrene 10mg, clotrimazole 50mg, white petrolatum 500mg, caroxane 900mg, ethylparaben 200mg, the balance was added to 2000mg with sorbitan sesquioleate, made into 1000 capsules.

[0029] The preparation method is as follows:

[0030] (1) Weigh white petrolatum according to the above formula, heat and dissolve together with some carrageenan, keep it warm at about 60°C, and set aside;

[0031] (2) Weigh promestrine and the remaining amount of oxalane together, stir to completely dissolve promestrine, then add clotrimazole to stir evenly, then add the weighed sorbitan sesquihalide After stirring and dissolving oleic acid ester and ethylparaben, the solution obtained in step 1 is mixed, and fully mixed with a high-speed homogenizer to obtain the content;

[0032] (3) Melt gelatin, glycerin, and water in conventional amounts at about 60°C, and vacuum degas the glue for...

Embodiment 2

[0034] Embodiment 2: prepare the soft capsule of pharmaceutical composition of the present invention

[0035] Preparation method is with embodiment 1, and formula is as follows:

[0036] Proestrene 8mg, clotrimazole 60mg, white petrolatum 500mg, caroxane 900mg, ethylparaben 200mg, the balance was added to 2000mg with sorbitan sesquioleate, made into 1000 capsules.

Embodiment 3

[0037] Embodiment 3: prepare the soft capsule of pharmaceutical composition of the present invention

[0038] Preparation method is with embodiment 1, and formula is as follows:

[0039] Proestrene 8 mg, clotrimazole 55 mg, white petrolatum 400 mg, carboxane 900 mg, ethylparaben 200 mg, and the balance was added to 2000 mg with sorbitan sesquioleate to make 1000 capsules.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicaments and provides a medicinal composition for treating colpomycosis. The medicinal composition comprises the following components in part by weight: 1 to 10 parts of promestriene and 50 to 80 parts of clotrimazole. Preferably, the medicinal composition comprises the following components in part by weight: 4 to 7 parts of promestriene and 60 to 70 parts of clotrimazole. The invention also provides a suppository, an ointment, topical lotion, a vaginal tablet, and a coating agent of the medicinal composition. The medicinal composition for treating the colpomycosis has the advantages of total efficiency of 100 percent in 20 days, obvious itching-removing and pain-killing effects, no irritation, comfortable local sensation, and wide clinical prospects.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a pharmaceutical composition for treating vaginitis. Background technique [0002] Estrogen deficiency is a common gynecological cause, especially in postmenopausal women, due to long-term estrogen deficiency, there will be a series of urogenital diseases, such as: vaginal dryness, dyspareunia, atrophic vagina with urinary incontinence Inflammation and postmenopausal local nutritional lesions must be treated with estrogen drugs. [0003] Promestrine is a steroid drug with formula C 22 h 32 o 2 , the molecular weight is 328.49, the CAS accession number is 39219-28-8, the EINECS accession number is 254-361-6, and the structural formula is as follows: [0004] [0005] Proestrene is an estrogen analogue, which can play an estrogen-like effect, help the repair of cervical and vaginal mucosal damage and the regeneration of vaginal lactic acid bacteria, so it can treat vaginal atrophy, d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/565A61K31/4174A61P15/02A61P31/10A61K9/06A61K9/00A61K9/02A61K9/66A61K9/20
Inventor 杨军
Owner 杨军
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap